

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 30<sup>th</sup> April, 2024

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai-400 001 (Maharashtra)

(BY BSE LISTING CENTRE)

**Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.**

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Audited Financial Results of the Company for the quarter and year ended on 31<sup>st</sup> March, 2024 along with the Statement of Assets and Liabilities as on 31<sup>st</sup> March, 2024 and Statement of Cash Flow for the year ended on 31<sup>st</sup> March, 2024 and Auditor's Report issued with unmodified opinion.

Further, a declaration duly signed by the Managing Director and the Chief Financial Officer of the company, pursuant to Regulation 33(3)(d) of the Listing Regulations, read with SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016 to the effect that Auditor's Report has been issued with unmodified opinion on the Audited Financial Results of the Company for the quarter and year ended on 31<sup>st</sup> March, 2024 is also enclosed herewith.

You are requested to kindly take the same on record.

Thanking You,  
Yours Faithfully

**FOR SARDA PROTEINS LTD**  
**For SARDA PROTEINS LTD**

  
Company Secretary

**AMIT KUMAR MODI**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**  
**M. NO.: A29371**

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)  
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)  
Contact No.: +91-7737822222; E Mail: sardaproteins@yahoo.com; Web: www.sardaproteins.com



# **S K AGARWAL & ASSOCIATES**

Chartered Accountants

111, 1st Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)

Mob : 9828115580 | Email : cabhiwadi@gmail.com

## **INDEPENDENT AUDITOR'S REPORT**

**Independent Auditor's Report on the Quarterly and Year to Date Standalone Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To  
The Board of Directors of  
**SARDA PROTEINS LTD**  
B-536-537, Matsya Industrial Area,  
Alwar, Rajasthan- 301030.

### **Report on the Audit of the Financial Results**

#### **Opinion**

We have audited the accompanying statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2024 ("Statement") of Sarda Proteins Ltd ("the Company"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement;

- a. Is presented in accordance with the requirements of the Listing Regulations in this regard; and
- b. Gives a true and fair view in conformity with the applicable Indian Accounting Standards (IAS) as prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the company for the quarter and year ended March 31, 2024.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results



under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Financial Results.

### **Management's Responsibilities for the Financial Results**

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Statement. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the applicable Accounting Standards prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are also responsible for assessing the Company's ability to continue as going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Financial Reporting process of the Company.

### **Auditor's Responsibilities for the audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.



**We also:**

- (a) Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omission, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion through a separate report on the complete set off financial statements on whether the company has adequate internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- (d) Conclude on the appropriateness of Board of Directors'/ management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.
- (f) Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the company to express an opinion on the Annual Financial Results.

Materiality is the magnitude of misstatements in the statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Others Matters**

The statement includes Financial Results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, as required under the Listing Regulations.

Our opinion on the statement is not modified in respect of the above matter.

**For S K Agarwal & Associates**  
**Chartered Accountants**  
**FRN: 014841C**



**CA Ekta Kapoor**  
**Partner**  
**M. No.: 550801**  
**UDIN : 24550801BKEELM9699**



**Place : Bhiwadi**  
**Date : 30.04.2024**

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024**

Rs. in Lakhs

S. No.	Particulars	Quarter ended			Year ended	
		31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Audited)	31.03.2024 (Audited)	31.03.2023 (Audited)
I	Revenue from operation	6.01	99.99	73.81	129.58	579.52
II	Other Income	4.10	4.21	4.05	16.53	15.98
III	<b>Total Revenue (I+II)</b>	<b>10.11</b>	<b>104.20</b>	<b>77.86</b>	<b>146.11</b>	<b>595.50</b>
IV	Expenses					
	Cost of Material Consumed	-	-	-	-	-
	Purchase of Stock -in- Trade	0.01	97.07	71.36	120.71	571.77
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-
	Employee Benefit Expenses	5.55	3.65	3.11	14.56	13.48
	Finance cost	0.01	-	-	0.01	-
	Depreciation and Amortisation Expenses	-	-	-	-	-
	Other expenses	2.60	2.79	2.76	8.95	8.96
	<b>Total Expenses</b>	<b>8.16</b>	<b>103.51</b>	<b>77.23</b>	<b>144.23</b>	<b>594.21</b>
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	1.95	0.69	0.63	1.88	1.29
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(Loss) before extraordinary items and tax (V-VI)	1.95	0.69	0.63	1.88	1.29
VIII	Extraordinary Items	-	-	-	-	-
IX	Profit/(Loss) Before tax (VII-VIII)	1.95	0.69	0.63	1.88	1.29
X	Tax Expense:					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	(0.05)	-	4.60	(0.05)	4.60
XI	Profit/(Loss) for the period from continuing operations (VII-VIII)	2.01	0.69	(3.97)	1.94	(3.31)
XII	Profit/(Loss) for the period from discontinuing operations	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV	Profit/(Loss) for the period (XI+XIV)	2.01	0.69	(3.97)	1.94	(3.31)
XVI	Other Comprehensive Income					
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and other comprehensive income for the period)</b>	<b>2.01</b>	<b>0.69</b>	<b>(3.97)</b>	<b>1.94</b>	<b>(3.31)</b>
XVII	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59	172.59
XVIII	Earnings per Equity Share (For discontinued and continuing Operations)					
	(1) Basic	0.12	0.04	(0.23)	0.11	(0.19)
	(2) Diluted	0.12	0.04	(0.23)	0.11	(0.19)

for S K Agarwal & Associates  
 FRN: 014841C  
 CA Ekta Kapoor  
 MRN: 550801  
 UDIN: 245508018KEELM9639

Place: Jaipur  
 Date: 30.04.2024

*Deepak*



on behalf of the Board  
 Sarda Proteins Ltd

Deepak Data (DIN: 01672418)  
 Managing Director



**STATEMENT OF ASSETS AND LIABILITIES AS ON 31ST MARCH, 2021**

Rs. in Lakhs

Particulars		Year ended	Year ended
		31.03.2021	31.03.2020
		(Audited)	(Audited)
<b>A. ASSETS</b>			
1	<b>Non-Current Assets</b>		
	a) Property, Plant and Equipment	0.01	0.01
	b) Capital work in progress	-	-
	c) Investment Property	-	-
	d) Goodwill	-	-
	e) Other Intangible Assets	-	-
	D Intangible Assets under Development	-	-
	g) Biological Assets other than bearer plants	-	-
	h) Financial Assets	-	-
	i) Investments	-	0.13
	ii) Trade Receivables	-	-
	iii) Loans	-	-
	1) Deferred Tax Assets (net)	13.55	13.49
	j) Other non-current Assets	-	-
2	<b>Current Assets</b>		
	a) Inventories	-	-
	b) Financial Assets	-	-
	i) Investments	-	-
	ii) Trade Receivables	-	-
	iii) Cash and Cash Equivalents	-	0.25
	iv) Bank Balances and other than (iii) above	11.87	18.19
	v) Loans	215.00	205.00
	v) Others	3.05	3.58
	c) Current Tax Assets (net)	-	-
	d) Other Current Assets	-	-
	<b>Total Assets</b>	<b>243.48</b>	<b>240.45</b>
<b>B. EQUITY AND LIABILITIES</b>			
1	<b>Equity</b>		
	a) Equity Share Capital	250.45	250.45
	b) Other Equity	(13.16)	(15.19)
2	<b>Liabilities</b>		
	<b>Non-current Liabilities</b>		
	a) Financial Liabilities		
	i) Borrowings	-	-
	ii) Trade Payables	-	-
	A) Total Outstanding dues to MSEs	-	-
	B) Total Outstanding dues to Creditors other than MSEs	-	-
	iii) Other Financial Liabilities	-	-
	b) Provisions	4.34	2.79
	c) Deferred Tax Liabilities (net)	-	-
	d) Other Non Current Liabilities	-	-
	<b>Current Liabilities</b>		
	a) Financial Liabilities		
	i) Borrowings	-	-
	ii) Trade Payables	-	-
	A) Total Outstanding dues to MSEs	-	-
	B) Total Outstanding dues to Creditors other than MSEs	-	-
	iii) Other Financial Liabilities	-	-
	b) Other Current Liabilities	1.84	2.31
	c) Provisions	-	-
	d) Current Tax Liabilities (net)	-	-
	<b>Total Equity and Liabilities</b>	<b>243.48</b>	<b>240.45</b>

For S.K. Agarwal & Associates  
 FRN 014841C  
 CA Ekta Kapoor  
 MRN: 550801  
 UDIN: 245508018KEELM9699  
 Place: Jaipur  
 Date: 30.04.2024

*Sub*



on behalf of the Board  
 Sarda Proteins Ltd



Deepak Datta (DIN: 01672415)  
 Managing Director

**CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2024**

Rs. in Lakhs

Particulars		Year ended	Year ended
		31.03.2024 (Audited)	31.03.2023 (Audited)
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
	Net Profit before Tax and Extraordinary Items	1.88	1.29
<b>A</b>	<b>ADJUSTMENT FOR</b>		
	Depreciation	-	-
	Interest Received	(16.53)	(15.98)
	Profit on Sale of Investment	0.13	-
	Dividend	-	-
	(Profit) / Loss on sale of Fixed Assets	-	-
	Interest Paid	0.01	-
	<b>Operating Profit/(Loss) before Working Capital Charges</b>	<b>(14.51)</b>	<b>(14.69)</b>
	<b>ADJUSTMENT FOR</b>		
	Trade and other Receivables	(9.67)	(13.92)
	Inventories	-	-
	Trade & other Payables	1.09	(1.51)
	Other Non Current Assets	-	-
	Cash Generated from Operations	(8.58)	(19.12)
	Direct Taxes Paid	-	-
	<b>Net Cash from Operating Activities</b>	<b>(23.09)</b>	<b>(30.12)</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Capital Expenditure	-	-
	Sale of Fixed Assets	-	-
	Profit/ (Loss) on sale of Fixed Assets	(13.00)	-
	Profit on sale of Investment	13.00	-
	Sale of Investment	-	-
	Interest Received	16.53	15.98
	Dividend Received	-	-
	<b>Net Cash Received from Investing Activities</b>	<b>16.53</b>	<b>15.98</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Proceeds from Long Term Borrowings	-	-
	Proceeds from Short Term Borrowings	-	-
	Interest Paid	(0.01)	-
	<b>Net Cash Inflow/ (Outflow) from Financing Activities</b>	<b>(0.01)</b>	<b>-</b>
	<b>Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(6.57)</b>	<b>(14.14)</b>
	Cash & Cash Equivalents (Opening)	18.44	32.58
	Cash & Cash Equivalents (Closing)	11.88	18.44

**Notes:**

1. Disclosure :-	As on 31.03.2024
Outstanding Qualified Borrowings at the start of the financial year	-
Outstanding Qualified Borrowings at the end of the financial year	-
Highest credit rating of the company (where the credit rating relates to the unsupported bank borrowing or plain vanilla bonds of an entity, which have no structuring/ support built in)	NA
Incremental borrowing done during the year (qualified borrowing)	-
Borrowings by way of issuance of debt securities during the year	-

- The above results were approved by Audit Committee and Board of Directors in their meeting held on 30.04.2024
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 31-Mar-2024 nor any pending as on 01-Apr-2024.
- The Figures for the last quarter are the balancing figures between the audited figures of the financial years ended and the published results upto the third quarter of the respective financial years.
- Figures for the previous period have been regrouped/reclassified wherever considered necessary so as to confirm to the classification of the current period.

**For S K Agarwal & Associates**

FRN : 014841C

CA & Kta Kapoor

MRN: 550801


UDIN: 24550801BKEELM9699

Place: Jaipur  
Date: 30.04.2024

*Pulse!*



on behalf of the Board  
Sarda Proteins Ltd



Deepak Datta (DIN: 01622415)  
Managing Director



CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 30<sup>th</sup> April, 2024

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001 (Maharashtra)

(BY BSE LISTING CENTRE)

**Sub: Declaration pursuant to Regulation 33(3) (d) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.**

Dear Sir / Ma'am,

## DECLARATION

We, Deepak Data, Managing Director and Shipra Gandhi, Chief Financial Officer of Sarda Proteins Ltd (CIN: L15142RJ1991PLC006353) having its Registered office situated at B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan) hereby declare that M/s S K Agarwal & Associates (FRN: 014841C), Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on Audited Financial Results for the quarter and year ended on 31<sup>st</sup> March, 2024.

This declaration is given in compliance to Regulation 33(3)(d) of the Listing Regulations as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 read with SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

You are requested to kindly take the same on record.

Thanking You,  
Yours Faithfully

For Sarda Proteins Ltd  
For SARDAS PROTEINS LTD.

  
Director

Deepak Data  
Managing Director  
DIN: 01672415

For SARDAS PROTEINS LTD.

  
CFO

Shipra Gandhi  
Chief Financial Officer  
PAN: AUNPG0520E

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 03<sup>rd</sup> April,2024

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001 (Maharashtra)

Sub: Non-Applicability of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26<sup>th</sup> November, 2018 with regard to Fund Raising by Issuance of Debt Securities by Large Entities

Ref: Sarda Proteins Ltd. Scrip Code: 519242, Security ID: SRDAPRT

Dear Sir/Ma'am,

We hereby confirm that we are not a Large Corporate as defined in the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26<sup>th</sup> November, 2018. Therefore, the filing of the Initial Disclosure in Annexure A of the said Circular for the year ended 31<sup>st</sup> March, 2024 is not required.

You are requested to kindly take the same on record.

Thanking You,  
Yours Sincerely

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD

  
Company Secretary

AMIT KUMAR MODI  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
M.NO.: A29371

**Reg. Office:** B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

**Corp. office:** Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

**Contact No.:** +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 03<sup>rd</sup> April, 2024

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001 (Maharashtra)

Sub: Confirmation of Non-Applicability of Annual Disclosure under SEBI Circular SEBI/HO/DDHS/P/CIR/ 2021/613 dated August 10, 2021 (updated as on April 13, 2022).

Ref: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT

Dear Sir/Ma'am,

With reference to the SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 and SEBI circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 (updated as on April 13, 2022) in respect of fund raising by issuance of debt securities by Large Corporate (LC), we hereby confirm that Sarda Proteins Limited ("Company") is "Not a Large Corporate" as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021.

Please find enclosed Annexure for non-applicability of Annual Disclosure in this regard.

You are requested to kindly take the same on your record.

Thanking You,  
Yours Sincerely

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD.

  
Company Secretary

AMIT KUMAR MODI  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
M.NO.: A29371

**Reg. Office:** B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

**Corp. office:** Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

**Contact No.:** +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Annexure

## Annual Disclosure to be made by an entity identified as a LC\*

1. Name of the Company : Sarda Proteins Ltd
2. CIN : L15142RJ1991PLC006353
3. Report filed for FY : 2023-24
4. Details of the current block (all figures in Rs. Crore) : Not Applicable

S. No.	Particulars	Details
1	2-year block period (specify financial years)	Not Applicable
2	Incremental borrowing done in FY 2023-24 (T) (a)	Not Applicable
3	Mandatory borrowing to be done through debt securities in FY 2023-24 (T) (b) = (25% of a)	Not Applicable
4	Actual borrowing done through debt securities in FY 2023-24 (T)(c)	Not Applicable
5	Shortfall in the borrowing through debt securities, if any, for FY 2022-23 (T-1) carried forward to FY 2023-24 (T). (d)	Not Applicable
6	Quantum of (d), which has been met from (c) (e)	Not Applicable
7	Shortfall, if any, in the mandatory borrowing through debt securities for FY 2023-24 (T) {after adjusting for any shortfall in borrowing for FY 2022-23 (T-1) which was carried forward to FY 2023-24 (T)} (f)= (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	Not Applicable

## 5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs. crore):

S. No.	Particulars	Details
1	2-year block period (specify financial years)	Not Applicable
2	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	Not Applicable

\*In cases, where an entity is not categorised as LC for FY (T), however was LC for FY (T- 1), and there was a shortfall in the mandatory bond borrowing for FY (T-1), which was carried forward to FY (T), the disclosures as prescribed in this annexure shall be made by the entity for FY (T).

#(d) and (e) are the same as mentioned at sl. nos. 5 and 6 in the table given at point no. 4 of this annexure.

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, SEBI circular No. SEBI/HO/DOHS/P/CIR/2021/613 dated August 10, 2021 (updated as on April 13, 2022).

FOR SARDA PROTEINS LTD


For SARDA PROTEINS LTD

  
Company Secretary

AMIT KUMAR MODI  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
M.NO.: A29371  
CONTACT DETAILS: 7737822222  
DATE: 03<sup>RD</sup> APRIL, 2024

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD.

  
CFO

SHIPRA GANDHI  
CHIEF FINANCIAL OFFICER  
CONTACT DETAILS : 9680680500

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

Contact No.: +91-7737822222; E Mail: sardaproteins@yahoo.com; Web: www.sardaproteins.com